Achieve Life Sciences announced the appointment of Benjamin Halladay as its new Chief Financial Officer (CFO), effective October 5, 2026. Mr. Halladay will succeed Mark Oki, who is stepping down from the role on the same date. The company stated that Mr. Oki's departure is not the result of any disagreement regarding the company's financial statements or disclosures.

Key Details

  • New Appointee: Benjamin Halladay, age 40, previously served as CFO of Esperion Therapeutics, Inc. from November 2022 to September 2026.
  • Compensation Package: Mr. Halladay's employment agreement includes a $525,000 annual base salary, a discretionary annual bonus of up to 40% of his base salary, an option to purchase 200,000 shares, and 200,000 restricted stock units (RSUs).
  • Effective Date: The appointment and the departure of the current CFO, Mark Oki, are both effective as of October 5, 2026.